- Home
- MLP vs CRVS Comparison
MLP vs CRVS Comparison
Compare MLP & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLP
- CRVS
- Stock Information
- Founded
- MLP 1909
- CRVS 2014
- Country
- MLP United States
- CRVS United States
- Employees
- MLP N/A
- CRVS N/A
- Industry
- MLP Real Estate
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- MLP Finance
- CRVS Health Care
- Exchange
- MLP Nasdaq
- CRVS Nasdaq
- Market Cap
- MLP 343.9M
- CRVS 305.4M
- IPO Year
- MLP 1972
- CRVS 2016
- Fundamental
- Price
- MLP $17.50
- CRVS $5.75
- Analyst Decision
- MLP
- CRVS Strong Buy
- Analyst Count
- MLP 0
- CRVS 4
- Target Price
- MLP N/A
- CRVS $15.00
- AVG Volume (30 Days)
- MLP 15.7K
- CRVS 518.7K
- Earning Date
- MLP 08-14-2025
- CRVS 08-07-2025
- Dividend Yield
- MLP N/A
- CRVS N/A
- EPS Growth
- MLP N/A
- CRVS N/A
- EPS
- MLP N/A
- CRVS N/A
- Revenue
- MLP $16,843,000.00
- CRVS N/A
- Revenue This Year
- MLP N/A
- CRVS N/A
- Revenue Next Year
- MLP N/A
- CRVS N/A
- P/E Ratio
- MLP N/A
- CRVS N/A
- Revenue Growth
- MLP 74.59
- CRVS N/A
- 52 Week Low
- MLP $14.05
- CRVS $2.54
- 52 Week High
- MLP $26.46
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- MLP 53.69
- CRVS 65.10
- Support Level
- MLP $16.41
- CRVS $5.28
- Resistance Level
- MLP $17.49
- CRVS $5.64
- Average True Range (ATR)
- MLP 0.56
- CRVS 0.30
- MACD
- MLP 0.10
- CRVS 0.03
- Stochastic Oscillator
- MLP 81.63
- CRVS 77.70
About MLP Maui Land & Pineapple Company Inc.
Maui Land & Pineapple Co Inc is a landholding and operating company. ML&P owns, develops, sells, and manages residential, resort, commercial, agricultural, and industrial real estate. It operates in three segments: Land Development & Sales which includes land planning and entitlement, development, and sales activities; Leasing operations include residential, resort, commercial, agricultural, industrial land and property leases; and Resort Amenities segment, which include a membership program that provides certain benefits and privileges within the Kapalua Resort for its members. The majority of its revenue is derived from the Leasing segment. Leasing revenue is generated from restaurants, retail outlets, office buildings, warehouses, and other resort activities.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).